Idiopathic pulmonary fibrosis (IPF) is a fatal disease with limited treatment options and extensive gene expression changes identified in the lung parenchyma. Multiple lines of evidence suggest that epigenetic factors contribute to dysregulation of gene expression in IPF lung. Most importantly, risk factors that predispose to IPF -age, sex, cigarette smoke, and genetic variants -all influence epigenetic marks. This review summarizes recent findings of association of DNA methylation and histone modifications with the presence of disease and fibroproliferation.
INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a late-age-ofonset lung disease with a median survival of only 3 years characterized by progressive scarring of the pulmonary parenchyma that leads to progressive loss of lung function with dyspnea and hypoxemia, ultimately resulting in respiratory failure and death. The prevalence of IPF is estimated at 63 individuals in 100 000 in the USA [1] , with the prevalence and mortality in pulmonary fibrosis increasing as our population ages [2] . Treatment options for IPF are limited to two recently approved drugs that slow down disease progression [3, 4] . We are therefore in need of prevention and additional treatment strategies for this fatal lung disease.
The paradigm about disease pathogenesis has shifted from beliefs that IPF is a result of chronic inflammation [5] to the idea that it results from excessive, sequential injury and/or aberrant wound healing of the alveolar epithelium [6] and to more recent suggestions that the distal airway epithelium may also be important in disease development IPF [29] [30] [31] [32] [33] [34] [35] . Gene expression changes are dramatic and involve genes associated with extracellular matrix (ECM) formation, degradation, and signaling; smooth muscle markers; growth factors; developmental pathways; and genes encoding immunoglobulins, complement, chemokines, and other host defense/innate immune genes. We also recently identified two molecular subtypes of IPF based on a strong gene expression signature of cilium-associated genes [11] . Expression of MUC5B, the strongest and most replicated genetic risk factor for IPF [8, 36, 37, 38 & ,39 & , 40, 41] , is highly correlated to the expression of cilium genes. This is also the case for MMP7, an ECM gene that has emerged as the main expression biomarker for IPF [30, 33, 42] and was recently shown to play a role in attenuating ciliated cell differentiation during wound repair [43] . Although gene expression studies in aggregate have been successful in identifying molecular processes that are dysregulated in IPF lung, we know much less about how expression of these genes is regulated at the transcriptional, post-transcriptional, and post-translational levels.
INTRODUCTION TO EPIGENETIC MECHANISMS
Epigenetic processes translate environmental exposures into regulation of chromatin, which shapes the identity, gene expression profile, and activity of specific cell types that participate in disease pathophysiology [44] . They are emerging as key mechanisms that mediate the effects of both genetics and the environment on gene expression and disease [45, 46] . Traditionally, epigenetic processes refer to DNA methylation and histone modifications. Although noncoding RNAs are often considered a part of the epigenome, this review will focus only on DNA methylation and histone modifications.
Methylation of cytosine residues in CpG dinucleotides within the context of CpG islands is the simplest form of epigenetic regulation. DNA methyltransferases (de-novo DNMT3A/B and maintenance DNMT1) are enzymes responsible for DNA methylation, whereas the ten-eleven translocation family of enzymes actively demethylate DNA through the 5-hydoxymethylcytosine intermediate [47] . Traditional view of DNA methylation is that hypermethylation of CpG islands in gene promoters leads to gene silencing, whereas hypomethylation leads to active transcription [48, 49] , but we now know that methylation of less CpG dense regions near islands ('CpG island shores') [50, 51] and within gene bodies [52
&&
,53] is also important in regulation of gene transcription and alternative splicing. Although the canonical inverse relationships of methylation and expression are predominant in the genome, direct relationships also exist especially for methylation marks in gene bodies and for those associated with alternative splicing [53, 54] .
Acetylation and methylation are the most common modifications of histone tails that occur at specific sites and residues, and control gene expression by regulating DNA accessibility to RNA polymerase II and transcription factors. Histone acetyltransferases (HATs) acetylate histone tails, histone deacetylases (HDACs) remove acetyl groups from histone tails, and bromodomain (Brd) proteins are chromatin readers that recognize and bind acetylated histones and play a key role in transmission of epigenetic memory across cell divisions and transcription regulation [55, 56] . Similarly, histone methyltransferases add the methyl groups to histone tails, whereas histone demethylases remove them [55, 56] . A number of modifications at specific sites and residues regulate chromatin accessibility [57,58 && ].
EPIGENETICS AND IDIOPATHIC PULMONARY FIBROSIS: THE POTENTIAL LINKS
Given what we know about IPF and epigenetic marks, several lines of evidence support a critical role for control of gene expression in IPF lung by DNA methylation and histone modifications ( Fig. 1 ). First, IPF is a disease of the elderly, and changes in DNA methylation, histone modifications, and gene expression occur as we age [59] [60] [61] . Genome-wide studies in aging cells and tissues have revealed the occurrence of stochastic
KEY POINTS
Epigenetic marks, just like pulmonary fibrosis, are affected by aging, environmental exposures, genetic variants, and are important in developmental pathways that are aberrantly recapitulated in IPF lung.
Expression of genes and pathways that are key in the fibroproliferative response is regulated by DNA methylation and histone modifications.
Genomic studies of DNA methylation and histone modifications in IPF lung tissue and specific cells from the IPF lung are just emerging.
Epigenetic marks that are shaped by the genetics and environment and influence transcription of specific genes will empower us to develop biologically driven therapeutics and biomarkers for secondary prevention of this disease.
changes in DNA methylation, also referred to as drift [62] . Stochastic profibrotic DNA methylation drift could predispose to the development of the disease in susceptible individuals [63 && ]. Similarly, sex is known to play a role in tissue-specific DNA methylation patterns [64] [65] [66] [67] [68] and being of male sex is a risk factor for the development of IPF [1] .
Second, IPF is an environmental lung disease [69, 70] . It is well established that environmental exposures strongly influence epigenetic marks [71] . Cigarette smoke, the main environmental risk factor for IPF, has an influence on the methylome [72] [73] [74] and on methylation of specific promoters in genes involved in pathogenesis of IPF such as WNT7A [75] . Recent work identified extensive genomic changes in DNA methylation in small airway epithelium of smokers compared with smokers with corresponding modulation of gene expression [76 & ]. Other recent studies have shown how cigarette smoke influences histone modifications and chromatin accessibility [77] [78] [79] .
Third, IPF is also a genetic disease [38 & ,39 & ,80], and genetic factors also influence epigenetic marks. An individual's genetic background influences epigenetic marks in two ways -by direct inheritance (imprinted loci) [81] and by genetic variants that segregate with disease exerting their effects through epigenetic modifications, such as the case of haplotype-specific methylation. In addition to investigation at specific loci, genome-wide studies demonstrate a strong genetic component to interindividual variation in methylation [82] [83] [84] and histone modification profiles [85] [86] [87] .
Finally, epigenetic marks are crucial in lung development, and aberrant recapitulation of the developmental program following injury is a hallmark feature of IPF [27] . DNA methylation and histone modifications determine cell fate during organ development by controlling tissue-specific expression [88] . Epigenetic control of gene expression is also involved in lung epithelial cell differentiation [89] and developmental pathway signaling [90, 91] .
TARGETED STUDIES OF DNA METHYLATION AND HISTONE MODIFICATIONS IN LUNG FIBROSIS
Several targeted studies have shown that epigenetic modulation (both DNA methylation and histone marks) regulates expression of genes and miRNAs involved in pathogenesis of IPF (Table 1) , namely cyclooxygenase-2 [92, 93] , chemokine IFN-g-inducible protein 10 [94] , Thy-1 (CD90) [95, 96] , p14 alternative reading frame (ARF) [97] , a-smooth muscle actin [98, 99] , and miR-17 $ 92 cluster [100 && ]. Similarly, molecular processes of high relevance to pulmonary fibrosis are also epigenetically regulated; this has been demonstrated specifically for fibroblast apoptosis [101, 102] , cell senescence [103] , and innate immunity [104] in IPF. These studies of DNA methylation and histone modifications in specific genes, miRNAs, and molecular processes have also shown a direct link to fibroproliferative phenotypes. For example, Dakhlallah et al. [100 && ] identified a DNMT1-controlled feedback loop that contributes to the IPF fibroblast phenotype and ECM deposition. Another study has linked tranforming growth factor beta 1 signaling, lung development, and histone modifications [105] . Taken together, these targeted studies have provided crucial information on the role of DNA methylation and histone modifications in regulation of gene expression in some of the key genes, miRNAs, pathways, and molecular processes that are hallmarks of IPF.
GENOMIC PROFILES OF DNA METHYLATION IN IDIOPATHIC PULMONARY FIBROSIS
Genome-wide assessments of epigenetic marks in IPF are limited to DNA methylation profiles at the present time ( Table 1 ). The first two studies of genomic methylation profiles of IPF lung tissue used arrays with probes covering CpG islands and promoters. Despite the limited coverage of early array platforms, the first two studies of genomic methylation profiles identified extensive DNA methylation changes in IPF lung tissue [106, 107] . A more recent study used the same platform as in Sanders et al.
[107] to also show substantial changes in DNA methylation in fibroblasts, the key effector cell in fibrosis, of patients with IPF compared with controls [108 && ].
The most comprehensive study of IPF lung tissue to date was led by our group and interrogated 4.6 million CpG sites distributed across the human ]. This analysis identified 2130 significant differentially methylated regions (DMRs), of which 60% are in CpG island shores, similar to published findings in cancer [110] . Seven hundred and thirty-eight DMRs are associated with significant changes in gene expression and enriched for canonical inverse relationship between methylation and expression. An additional analysis of the relationship of methylation marks to expression changes identified methylation marks that control both cis-and trans-regulation of gene expression, with an enrichment for cis-relationships. This analysis also identified five trans-relationships, where a methylation change at a single DMR is associated with transcriptional changes in a substantial number of genes; four of these DMRs are near transcription factors. Taken together, these findings suggest not only widespread DNA methylation changes in IPF lung tissue, but also a substantial effect of these methylation changes on gene expression. Although it is unknown whether the methylation changes we have identified are the result of the disease or are causative, given that several risk factors for IPF are independently associated with changes in DNA methylation, it is likely that the latter at least contributes to the methylation pattern.
In addition to replication of the published findings, one of the most important directions for the field of IPF epigenomics is to begin to understand cell-specific patterns of DNA methylation and gene expression in the lung. For example, our study showed hypermethylation and reduced expression of the castor zinc finger 1 (CASZ1) transcription factor in whole lung tissue, but the same DMRs were hypomethylated in alveolar type II cells isolated from IPF lungs [109 && ]. In accordance with these findings, immunohistochemical staining showed loss of expression in airway epithelium and concomitant increase in expression of CASZ1 in the alveolar epithelium in IPF lung tissue sections compared with histologically normal lung [109 && ]. Isolation of specific cell types would also allow for profiling of histone modifications to paint a more complete picture of the role of epigenetic regulation of gene expression in IPF lung.
METHYLATION CHANGES WITHIN THE IDIOPATHIC PULMONARY FIBROSIS GENETIC LOCI
Recent work in the field of genetics of IPF has made it clear that there is a strong genetic component to this disease. ,39 & ] and identified methylation changes in genes within five of these loci [109 && ]. Of special interest are genes that are differentially expressed in IPF lung and whose expression may be regulated by both genetic variants and DNA methylation. As more genetic discoveries are made and the loci that have already been associated fine mapped, it is highly likely that additional candidate genes will emerge.
MUC5B
The strongest genetic candidate gene is MUC5B whose expression appears to be regulated at least in part by the IPF-associated promoter polymorphism rs35705950 [8, 111] . This MUC5B promoter variant is associated with a 34.1-fold increase in MUC5B expression in lung tissue among unaffected subjects and a 5.3-fold increase among IPF patients, with IPF patients expressing 14.1-fold more MUC5B than unaffected controls. Although our genomic methylation study did not identify DMRs near the MUC5B gene, there is reasonable evidence for the potential role of DNA methylation in regulation of MUC5B expression. The variant is approximately 3 kb upstream of the MUC5B transcriptional start site, in an area of open chromatin, a dense region of ChIP-seq hits, in a highly conserved genomic region and within a CpG island, strongly suggesting that this region is important for gene regulation. DNase hypersensitivity assays indicate areas of open transcriptionally active chromatin [112] . In the ENCODE project, 19 of the 125 analyzed cell lines, including the lung epithelial carcinoma cell line A549, have open chromatin in the chromosomal region overlapping the MUC5B promoter polymorphism (chr11:1241201-1241350 for A549) [112] . Areas of open chromatin are often associated with binding of enhancer, silencer, and other regulator elements [112,113 & ]. Large-scale ChIP-seq analysis, also part of the ENCODE project, has demonstrated the binding of at least 20 transcription factors to the A549-specific DNase hypersensitivity region described above, with 18 transcription factors predicted to bind in the region overlapping the common polymorphism [114,115 & ,116] . Moreover, the promoter polymorphism is located within a $200 bp CpG island motif (chr11:1241162-1241364), which is of particular interest given that the variant (G to T transversion) allele at rs35705950 disrupts a CpG motif, and therefore directly affects methylability of the adjacent cytosine. Although rs35705950 provides a very pointed example of a potential epigenetic regulator, more global changes in DNA methylation have also been associated with MUC5B expression. Vincent et al. [117, 118] previously showed that in-vitro exposure to 5-azacytidine, a global DNA demethylating agent, can alter MUC5B expression. We also know that the region of chromosome 11 becomes differentially methylated in some forms of cancer [119] . Understanding regulation of MUC5B expression by a combination of DNA methylation in IPF lung and the rs35705950 polymorphism is an important future direction.
Toll interacting protein
Toll interacting protein (TOLLIP), a gene involved in innate immunity and inflammation, has emerged as a potential genetic candidate in addition to MUC5B on chromosome 11 [39 & ], is 1.6-fold downregulated, and we identified two intronic DMRs in TOLLIP that are approximately 11% hypermethylated in IPF compared with controls. Hypermethylation of TOLLIP has recently been observed in synovial fibroblasts of patients with rheumatoid arthritis [120] . 
PROMISE FOR TREATMENT OPTIONS
Identification of key epigenetic marks that are shaped by the genetics and environment and influence transcription of specific genes will not only help us have a better understanding of etiology and heterogeneity of IPF, but will also empower us to develop biologically driven therapeutics and biomarkers for secondary prevention of this disease. DNA methylation changes have been shown to drive tumor formation and malignant progression [122] , and as such have established basic mechanisms for disease pathogenesis, as well as targets for intervention in cancer. DNMT inhibitors have been approved for the treatment of myelodysplastic syndrome [123, 124] and are in clinical trials for the treatment of solid tumors [125, 126] . Although currently available DNMT inhibitors lack specificity for gene(s) of interest, locus-specific therapies are currently being developed using genome-editing technologies [122, 127] or taking advantage of recently discovered DNMT1-interacting noncoding RNAs [128] . In addition, current Food and Drug Administration-approved and in-development histone mark-modifying drugs are effective in targeting specific gene loci and pathways [55, 129] and treating diseases such as lung cancer [130] . As a proof-ofprinciple for IPF, profibrotic phenotypes have been reversed in primary fibroblasts and the bleomycin mouse model by the Brd4 inhibitor JQ1 [131] , as well as HDAC inhibitors Spiruchostatin A [132] and suberoylanilide hydroxamic acid [102] .
CONCLUSION
Although we are in very early stages of using epigenetic marks as biomarkers and therapeutic targets in IPF, the potential is high and the next several years are likely to bring many exciting discoveries in this field that will hopefully bring us closer to better prognosticating and treating this fatal disease.
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